Vigil Neuroscience, Inc. (NASDAQ:VIGL) CEO Purchases $15,000.00 in Stock

Vigil Neuroscience, Inc. (NASDAQ:VIGL) CEO Ivana Magovcevic-Liebisch bought 4,000 shares of the stock in a transaction that occurred on Monday, November 20th. The shares were bought at an average cost of $3.75 per share, with a total value of $15,000.00. Following the completion of the purchase, the chief executive officer now directly owns 207,687 shares in the company, valued at $778,826.25. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Vigil Neuroscience Trading Down 8.8 %

Shares of Vigil Neuroscience stock traded down $0.35 on Monday, hitting $3.65. The stock had a trading volume of 708,860 shares, compared to its average volume of 52,843. Vigil Neuroscience, Inc. has a 52-week low of $3.60 and a 52-week high of $13.55. The stock has a market cap of $130.95 million, a price-to-earnings ratio of -1.79 and a beta of 2.78. The company’s 50 day moving average price is $6.34 and its 200 day moving average price is $7.61.

Wall Street Analyst Weigh In

Several research firms recently commented on VIGL. HC Wainwright reissued a “buy” rating and set a $24.00 target price on shares of Vigil Neuroscience in a research note on Thursday, September 14th. Wedbush reaffirmed an “outperform” rating and set a $23.00 price objective on shares of Vigil Neuroscience in a research report on Friday. JMP Securities assumed coverage on Vigil Neuroscience in a research report on Wednesday, October 18th. They set an “outperform” rating and a $23.00 price objective for the company. Finally, Mizuho lowered their price objective on Vigil Neuroscience from $15.00 to $13.00 in a research report on Thursday, August 10th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.20.

Institutional Trading of Vigil Neuroscience

Several institutional investors and hedge funds have recently made changes to their positions in VIGL. Royal Bank of Canada purchased a new stake in shares of Vigil Neuroscience in the 2nd quarter valued at about $33,000. California State Teachers Retirement System purchased a new stake in Vigil Neuroscience during the 2nd quarter valued at approximately $50,000. Wells Fargo & Company MN raised its stake in Vigil Neuroscience by 6,988.4% during the 2nd quarter. Wells Fargo & Company MN now owns 6,096 shares of the company’s stock valued at $57,000 after acquiring an additional 6,010 shares during the last quarter. American International Group Inc. purchased a new stake in Vigil Neuroscience during the 2nd quarter valued at approximately $73,000. Finally, MetLife Investment Management LLC purchased a new stake in Vigil Neuroscience during the 2nd quarter valued at approximately $86,000. 71.80% of the stock is owned by hedge funds and other institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.